Search

1. Applying a premium cap in Medicare Part B and Part D

Author(s):

Gangopadhyaya, Anuj, author
Holahan, John, author
Garrett, Bowen, author
Shartzer, Adele, author

Publication:

Washington, DC : Urban Institute, March 2023

Subject(s):

Health Equity -- economics
Health Policy
Insurance -- legislation & jurisprudence
Medicare Part B -- economics
Medicare Part D -- economics
Poverty -- economics
United States

2. Capping Medicare beneficiary Part D spending at $2,000: who would it help and how much?

Author(s):

Gangopadhyaya, Anuj, author
Garrett, Bowen, author

Publication:

Washington, DC : Urban Institute, March 2022

Subject(s):

Health Equity -- economics
Health Expenditures -- statistics & numerical data
Health Policy
Medicare Part D -- economics
Prescription Fees -- legislation & jurisprudence
Social Mobility
United States

3. Catastrophic coverage in the Medicare Part D drug benefit: which beneficiaries need it and how much are they spending?

Author(s):

Sen, Aditi P., author
Parasrampuria, Sonal, author
Anderson, Kelly E., author
Anderson, Gerard, author

Publication:

[New York, N.Y.] : The Commonwealth Fund, September 2020

Subject(s):

Health Expenditures -- statistics & numerical data
Medicare Part D -- economics
Financing, Personal
United States

4. A comparison of brand-name drug prices among selected federal programs

Author(s):

Baker, Colin, author
Laughery, Scott, author
Patel, Yash, author

Publication:

[Washington, DC] : Congressional Budget Office, February 2021

Subject(s):

Drug Costs -- statistics & numerical data
Government Programs -- economics
Medicaid -- economics
Federal Government
Medicare Part D -- economics
Prescription Drugs -- economics
United States
United States. Department of Defense
United States. Department of Veterans Affairs

5. Do states adjust Medicaid enrollment in response to capitation rates?: evidence from the Medicare Part D clawback

Author(s):

Quinby, Laura D., author
Wettstein, Gal, author

Publication:

Chestnut Hill, MA : Center for Retirement Research at Boston College, June 2019

Subject(s):

Capitation Fee
Dual MEDICAID MEDICARE Eligibility
Medicaid -- economics
Medicare -- economics
Medicare Part D -- economics
United States

6. Does Medicare Part D protect the elderly from financial risk?

Author(s):

Englehardt, Gary V., author
Gruber, Jonathan, author

Publication:

Chestnut Hill, MA : Center for Retirement Research at Boston College, June 2011

Subject(s):

Financing, Personal
Health Services for the Aged -- economics
Insurance Coverage -- economics
Medicare Part D -- economics
Risk Sharing, Financial
United States

7. Drug price increases that exceed inflation are costing Medicare Part D billions

Author(s):

Purvis, Leigh, author

Publication:

Washington, DC : AARP Public Policy Institute, June 2021

Subject(s):

Drug Costs
Inflation, Economic
Medicare Part D -- economics
Medicare Part D -- trends
Prescription Drugs -- economics
United States

8. The effect of Medicare Part D on evergreening, generic entry, and drug prices

Author(s):

Sanzenbacher, Geoffrey T., author
Wettstein, Gal, author

Publication:

Chestnut Hill, MA : Center for Retirement Research at Boston College, May 2019

Subject(s):

Drug Costs
Drugs, Generic -- economics
Medicare Part D -- economics
Patents as Topic
United States
United States. Food and Drug Administration
Medical Expenditure Panel Survey (U.S.)

9. High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia

Author(s):

Doshi, Jalpa A., author
Li, Bengxiang, author
Huo, Hairong, author
Pettit, Amy R., author
Kumar, Rishab, author
Weiss, Brendan M., author
Huntington, Scott F., author

Publication:

Philadelphia, PA : Leonard Davis Institute of Health Economics, 2016

Subject(s):

Cost Sharing
Drug Costs
Medicare Part D -- economics
United States

10. High-expenditure Medicare drugs often qualified for Orphan Drug Act incentives designed to encourage the development of treatments for rare diseases

Publication:

Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, September 2021

Subject(s):

Drug Development -- legislation & jurisprudence
Government Regulation
Medicare Part B -- economics
Medicare Part D -- economics
Orphan Drug Production -- economics
United States
United States. Department of Health and Human Services

11. How much does out-of-pocket medical spending eat away at retirement income?

Author(s):

McInerney, Melissa, author
Rutledge, Matthew S., author
King, Sara Ellen., author

Publication:

Chestnut Hill, MA : Center for Retirement Research at Boston College, October 2017

Subject(s):

Cost Sharing -- economics
Financing, Personal
Medicare Part D -- economics
Retirement -- economics
Social Security -- economics
United States

12. How will the Medicare Part D benefit change under current law and leading proposals?

Author(s):

Cubanski, Juliette, author
Neuman, Tricia, author

Publication:

San Francisco, CA : Henry J. Kaiser Family Foundation, October 2019

Subject(s):

Medicare Part D -- economics
Drug Costs
United States

13. Increases in reimbursement for brand-name drugs in Part D

Publication:

[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, June 2018

Subject(s):

Drug Costs -- trends
Drug Utilization -- trends
Insurance, Health, Reimbursement
Medicare Part D -- economics
United States
United States. Department of Health and Human Services

14. Closing the "doughnut hole" has helped protect millions of Medicare beneficiaries from high drug costs

Author(s):

Purvis, Leigh, author

Publication:

Washington, DC : AARP Public Policy Institute, March 2017

Subject(s):

Drug Costs
Insurance Coverage
Medicare Part D -- economics
United States
United States.

15. Medicare Part D

Author(s):

Steiner, David J., author

Publication:

[Toronto, Ontario] : Thomson Reuters, 23-December-2019

Subject(s):

Drug Costs
Medicare Part D -- economics
Medicare Part D -- legislation & jurisprudence
United States
United States. Department of Health and Human Services
Centers for Medicare & Medicaid Services (U.S.)

16. Medicare Part D

Author(s):

Steiner, David J., author

Publication:

[Toronto, Ontario] : Thomson Reuters, 19-December-2022

Subject(s):

Medicare Part D -- economics
Medicare Part D -- legislation & jurisprudence
Drug Costs -- legislation & jurisprudence
United States
Centers for Medicare & Medicaid Services (U.S.)

17. Medicare Part D and beneficiaries could realize significant spending reductions with increased biosimilar use

Publication:

Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, March 2022

Subject(s):

Biosimilar Pharmaceuticals
Drug Costs -- legislation & jurisprudence
Government Regulation
Medicare Part D -- economics
United States
United States. Department of Health and Human Services
Centers for Medicare & Medicaid Services (U.S.)

18. Medicare Part D and the financial protection of the elderly

Publication:

Chestnut Hill, MA : Center for Retirement Research at Boston College, c2009

Subject(s):

Financing, Personal
Health Expenditures
Insurance, Pharmaceutical Services -- economics
Medicare Part D -- economics
United States

19. Medicare Part D enrollee out-of-pocket spending: recent trends and projected impacts of the Inflation Reduction Act

Author(s):

Sayed, Bisma A., author
Finegold, Kenneth, 1957- author
Olsen, T. Anders, author
Ashok, Kaavya, author
Shutz, Sarah, author
Sheingold, Steven, author
De Lew, Nancy, author
Sommers, Benjamin D., author

Publication:

Washington, D.C. : Assistant Secretary for Planning and Evaluation, Office of Health Policy, July 7, 2023

Subject(s):

Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Medicare Part D -- economics
Medicare Part D -- statistics & numerical data
State Government
United States
United States.

20. Medicare Part D enrollee savings from elimination of vaccine cost-sharing

Author(s):

Sayed, Bisma A., author
Finegold, Kenneth, 1957- author
Ashok, Kaavya, author
Schutz, Sarah, author
De Lew, Nancy, author
Sheingold, Steven, author
Sommers, Benjamin D., author

Publication:

Washington, D.C. : Office of the Assistant Secretary for Planning and Evaluation, Office of Health Policy, March 15, 2023

Subject(s):

Cost Savings
Cost Sharing -- economics
Medicare Part D -- economics
Vaccines -- economics
United States
United States.

21. Medicare Part D: CMS should monitor effects of rebates on drug coverage and spending : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives

Publication:

Washington, DC : United States Government Accountability Office, September 19, 2023

Subject(s):

Government Regulation
Legislation, Medical
Medicare Part D -- economics
Medicare Part D -- organization & administration
Prescription Drugs -- economics
United States

22. Medicare Part D: CMS should monitor effects of rebates on plan formularies and beneficiary spending : report to congressional requesters

Publication:

Washington, DC : United States Government Accountability Office, September 2023

Subject(s):

Drug Costs
Government Regulation
Legislation, Medical
Medicare Part D -- economics
Medicare Part D -- organization & administration
Prescription Fees
United States
Centers for Medicare & Medicaid Services (U.S.)

23. Medicare Part D: a first look at plan offerings in 2016

Author(s):

Hoadley, Jack, author
Cubanski, Juliette, author
Neuman, Tricia, author

Publication:

Menlo Park, CA : Henry J. Kaiser Family Foundation, October 2015

Subject(s):

Insurance Benefits -- economics
Insurance Benefits -- statistics & numerical data
Insurance Coverage -- economics
Insurance Coverage -- statistics & numerical data
Insurance, Pharmaceutical Services -- economics
Insurance, Pharmaceutical Services -- statistics & numerical data
Medicare Part D -- economics
Medicare Part D -- statistics & numerical data
United States

24. Medicare Part D: a first look at prescription drug plans in 2018

Author(s):

Cubanski, Juliette, author
Damico, Anthony, author
Hoadley, Jack, author
Orgera, Kendal, author
Neuman, Tricia, author

Publication:

Menlo Park, CA : Henry J. Kaiser Family Foundation, October 2017

Subject(s):

Medicare Part C -- economics
Medicare Part C -- statistics & numerical data
Medicare Part C -- trends
Medicare Part D -- economics
Medicare Part D -- statistics & numerical data
Medicare Part D -- trends
United States

25. Medicare Part D: a first look at prescription drug plans in 2019

Author(s):

Cubanski, Juliette, author
Damico, Anthony, author
Neuman, Tricia, author

Publication:

San Francisco, CA : Henry J. Kaiser Family Foundation, October 2018

Subject(s):

Medicare Part D -- economics
Medicare Part D -- statistics & numerical data
United States

26. The Medicare drug benefit coverage gap: the basics

Publication:

Washington, D.C. : George Washington University, [2011]

Subject(s):

Insurance Coverage -- economics
Insurance Coverage -- legislation & jurisprudence
Insurance, Pharmaceutical Services -- economics
Insurance, Pharmaceutical Services -- legislation & jurisprudence
Medicare Part D -- economics
Medicare Part D -- legislation & jurisprudence
United States

27. Medicare's income-related premiums under current law and changes for 2019

Author(s):

Cubanski, Juliette, author
Neuman, Tricia, author

Publication:

San Francisco, CA : Henry J. Kaiser Family Foundation, October 2018

Subject(s):

Fees and Charges
Income
Medicare Part B -- economics
Medicare Part D -- economics
United States

28. No limit: Medicare Part D enrollees exposed to high out-of-pocket drug costs without a hard cap on spending

Author(s):

Cubanski, Juliette, author
Neuman, Tricia, author
Orgera, Kendal, author
Damico, Anthony, author

Publication:

Menlo Park, CA : Henry J. Kaiser Family Foundation, November 2017

Subject(s):

Drug Costs
Financing, Personal
Health Expenditures
Medicare Part D -- economics
Medicare Part D -- trends
United States

29. Part D plans generally include drugs commonly used by dual eligibles: 2019

Publication:

[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, June 2019

Subject(s):

Dual MEDICAID MEDICARE Eligibility
Formularies as Topic
Insurance Coverage
Medicare Part D -- economics
United States
United States.
Centers for Medicare & Medicaid Services (U.S.)

30. Prescription drugs: Department of Veterans Affairs paid about half as much as Medicare Part D for selected drugs in 2017 : report to the Ranking Member, Committee on the Budget, U.S. Senate

Publication:

Washington, DC : United States Government Accountability Office, December 2020

Subject(s):

Costs and Cost Analysis -- statistics & numerical data
Drug Costs -- statistics & numerical data
Government Regulation
Medicare Part D -- economics
United States
United States. Department of Veterans Affairs

31. Prescription drugs: U.S. prices for selected brand drugs were higher on average than prices in Australia, Canada, and France : report to the Chairman, Committee on the Budget, U.S. Senate

Publication:

Washington, DC : United States Government Accountability Office, March 2021

Subject(s):

Costs and Cost Analysis
Government Regulation
Medicare Part D -- economics
Prescription Drugs -- economics
United States

32. Prescription drugs: spending, use, and prices

Author(s):

Hayford, Tamara, author
Austin, David, author

Publication:

[Washington, DC] : Congressional Budget Office, January 2022

Subject(s):

Drug Costs
Health Expenditures -- trends
Medicaid -- economics
Medicare Part D -- economics
Prescription Drugs -- economics
United States

33. Prices for and spending on specialty drugs in Medicare Part D and Medicaid

Publication:

[Washington, DC] : Congressional Budget Office, March 2019

Subject(s):

Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Medicaid -- economics
Medicare Part D -- economics
Prescription Drugs -- economics
United States

34. Prices for and spending on specialty drugs in Medicare Part D and Medicaid: an in-depth analysis

Author(s):

Anderson-Cook, Anna, author
Maeda, Jared, author
Nelson, Lyle, author

Publication:

[Washington, DC] : Congressional Budget Office, March 2019

Subject(s):

Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Medicaid -- economics
Medicare Part D -- economics
Prescription Drugs -- economics
United States

35. Prices for top Medicare Part D drugs have more than tripled since entering the market

Author(s):

Purvis, Leigh, author

Publication:

Washington, DC : AARP Public Policy Institute, August 2023

Subject(s):

Drug Costs -- statistics & numerical data
Drug Costs -- trends
Medicare Part D -- economics
United States

36. Projected impacts for Asian Medicare enrollees

Publication:

Washington, D.C. : Office of the Assistant Secretary for Planning and Evaluation, Office of Health Policy, 2023

Subject(s):

Asian
Drug Costs -- legislation & jurisprudence
Forecasting
Medicare Part D -- economics
Medicare Part D -- legislation & jurisprudence
United States
United States.

37. Projected impacts for Black Medicare enrollees

Publication:

Washington, D.C. : Office of the Assistant Secretary for Planning and Evaluation, Office of Health Policy, September 25, 2023

Subject(s):

Black or African American
Cost Savings
Drug Costs -- legislation & jurisprudence
Forecasting
Medicare Part D -- economics
Medicare Part D -- legislation & jurisprudence
United States
United States.

38. Projected impacts for Latino Medicare enrollees

Publication:

Washington, D.C. : Office of the Assistant Secretary for Planning and Evaluation, Office of Health Policy, September 25, 2023

Subject(s):

Cost Savings
Drug Costs -- legislation & jurisprudence
Forecasting
Hispanic or Latino
Medicare Part D -- economics
Medicare Part D -- legislation & jurisprudence
United States
United States.

39. Questionable billing for compounded topical drugs in Medicare Part D

Publication:

[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2018

Subject(s):

Dermatologic Agents -- economics
Dermatologic Agents -- therapeutic use
Drug Compounding -- economics
Drug Utilization -- trends
Fraud
Insurance, Health, Reimbursement
Medicare Part D -- economics
Skin Cream -- economics
United States
United States. Department of Health and Human Services
Centers for Medicare & Medicaid Services (U.S.)

40. Rebates for brand-name drugs in Part D substantially reduced the growth in spending from 2011 to 2015

Publication:

[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, September 2019

Subject(s):

Drug Costs -- statistics & numerical data
Drug Costs -- trends
Insurance, Health, Reimbursement -- statistics & numerical data
Insurance, Health, Reimbursement -- trends
Medicare Part D -- economics
Medicare Part D -- statistics & numerical data
Medicare Part D -- trends
United States

41. The risk of misuse and diversion of buprenorphine for opioid use disorder in Medicare Part D continues to appear low: 2022

Publication:

[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, November 2023

Subject(s):

Buprenorphine
Drug Users -- statistics & numerical data
Government Regulation
Medicare Part D -- economics
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Prescription Drug Diversion -- statistics & numerical data
United States

42. Rx Watchdog report: comparative measures of price change for prescription drugs and other goods

Publication:

Washington, D.C. : AARP Public Policy Institute, c2009

Subject(s):

Drug Costs -- statistics & numerical data
Health Expenditures -- statistics & numerical data
Medicare Part D -- economics
Prescription Drugs -- economics
United States

43. Rx price watch report: trends in retail prices of brand name prescription drug widely used by Medicare beneficiaries : 2005 to 2009

Publication:

Washington, D.C. : AARP Public Policy Institute, c2010

Subject(s):

Drug Costs -- trends
Medicare Part D -- economics
Prescription Drugs -- economics
United States

44. Rx price watch report: trends in retail prices of generic prescription drugs widely used by Medicare beneficiaries : 2005 to 2009

Publication:

Washington, D.C. : AARP Public Policy Institute, c2011

Subject(s):

Drug Costs -- trends
Drugs, Generic -- economics
Medicare Part D -- economics
Prescription Drugs -- economics
United States

45. Rx price watch report: trends in retail prices of specialty prescription drugs widely used by Medicare beneficiaries : 2005 to 2009

Publication:

Washington, D.C. : AARP Public Policy Institute, c2012

Subject(s):

Drug Costs -- trends
Medicare Part D -- economics
Prescription Drugs -- economics
United States

46. Rx watchdog report: trends in manufacturer prices of brand name prescription drugs used by Medicare beneficiaries 2002 to 2007

Author(s):

Gross, David J.

Publication:

Washington, D.C. : AARP Public Policy Institute, c2008

Subject(s):

Drug Costs -- trends
Drug Prescriptions -- economics
Forecasting
Medicare Part D -- economics
United States

47. Rx watchdog report: trends in manufacturer prices of generic prescription drugs used by Medicare beneficiaries 2003 to 2007

Author(s):

Gross, David J.

Publication:

Washington, DC : AARP Public Policy Institute, c2008

Subject(s):

Drug Costs -- trends
Drugs, Generic -- economics
Medicare Part D -- economics
Forecasting
United States

48. Rx watchdog report: trends in manufacturer prices of prescription drugs used by Medicare beneficiaries, 2008 year-end update

Publication:

Washington, D.C. : AARP Public Policy Institute, c2009

Subject(s):

Drug Costs -- trends
Drugs, Generic -- economics
Medicare Part D -- economics
Prescription Drugs -- economics
United States

49. Searching for savings in Medicare drug price negotiations

Author(s):

Cubanski, Juliette, author
Neuman, Tricia, author

Publication:

San Francisco, CA : Henry J. Kaiser Family Foundation, April 2018

Subject(s):

Drug Costs
Medicare Part D -- economics
Negotiating
Prescription Drugs -- economics
United States

50. Summary of recent and proposed changes to Medicare prescription drug coverage and reimbursement

Author(s):

Cubanski, Juliette, author

Publication:

Menlo Park, CA : Henry J. Kaiser Family Foundation, February 2018

Subject(s):

Medicare Part B -- economics
Medicare Part D -- economics
Prescription Drugs -- economics
United States